Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Large Growth in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 120,900 shares, a growth of 19.2% from the November 15th total of 101,400 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average daily volume of 143,400 shares, the short-interest ratio is presently 0.8 days.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, November 13th. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $3.50.

Bolt Biotherapeutics Price Performance

Shares of NASDAQ:BOLT remained flat at $0.53 on Friday. The stock had a trading volume of 107,380 shares, compared to its average volume of 165,592. The company has a market capitalization of $20.20 million, a PE ratio of -0.31 and a beta of 0.93. Bolt Biotherapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $1.56. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. The stock’s 50 day simple moving average is $0.62 and its 200 day simple moving average is $0.67.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). The company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.02 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. Equities analysts forecast that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

Institutional Trading of Bolt Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Acuitas Investments LLC increased its stake in shares of Bolt Biotherapeutics by 21.7% during the second quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after buying an additional 112,555 shares during the period. Assenagon Asset Management S.A. bought a new position in Bolt Biotherapeutics during the 2nd quarter worth about $26,000. Finally, FMR LLC increased its position in Bolt Biotherapeutics by 33.2% during the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares during the period. Institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.